Non–Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology

Journal of the National Comprehensive Cancer Network 2026

View at publisher
Authors: Gregory J. Riely, Douglas E. Wood, Dara L. Aisner, Andrea L. Axtell, Jessica R. Bauman, A. Bharat, Joe Y. Chang, Aakash Desai, Thomas J. Dilling, Jonathan E. Dowell, Gregory A. Durm, S. Gettinger
+29 more Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. Lackner, Michael Lanuti, B. Levy, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Tejas Patil, Patricio M. Polanco, Jonathan W. Riess, Ana Lucia Ruano Mendez, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, A. Tam, Tawee Tanvetyanon, Jane Yanagawa, Edwin Yau, Karen Yun, Kristina Gregory, Lisa E. Hang
DOI: 10.6004/jnccn.2026.0017
Cited by: 18
References: 362

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable biomarkers.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Journal of the National Comprehensive Cancer Network
Publisher
Harborside Press, LLC
Volume
24
Issue
4
Publication date
1 April 2026
Language
EN